What did the federal judge rule regarding Colorado's price cap on Enbrel, and why?

Chief Judge Daniel Domenico granted a preliminary injunction blocking Colorado from enforcing its $600-per-dose ($31,200/year) price cap on Amgen's Enbrel, ruling that Amgen would likely suffer significant and irreparable harm from charging lower prices, which could disrupt its negotiations with wholesalers and distributors; he further stated that while Colorado has a legitimate interest in improving drug affordability, 'capping the price of a patented drug' is not a permissible option under current legal reasoning.

What was Colorado's specific price cap on Enbrel, when was it set to take effect, and how does it compare to the drug's list price?

In October, the Colorado Prescription Drug Affordability Board capped Enbrel’s price at $600 for a 50-milligram weekly dose — equivalent to $31,200 per year — effective January 1, 2027; this stands in stark contrast to the drug’s list price, which 'exceeds $100,000 per year.'

Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

Jul 1, 2026

A federal judge blocked Colorado's price cap on Amgen's arthritis drug Enbrel, ruling it violated federal patent law and threatened irreparable harm. The injunction preserves Amgen's pricing strategy for its top-selling product.

reuters

2026-07-01

Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

2026-07-21

Amgen Settles Shareholder Lawsuit Claiming It Hid $10.7 Billion Tax Bill

2026-07-31

Amgen Discloses Data Breach Involving Patient Health Information

2026-09-01

UK regulator suspends Amgen's Tavneos for new patients over unreliable data

Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

FAQ